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Severe hypoglycaemia (SH) remains a challenge to people with type 1 diabetes
(T1DM), and new-generation basal insulins may improve patient outcomes. This post
hoc meta-analysis explored the risk of SH with insulin glargine 300 U/mL (Gla-300)
versus glargine 100 U/mL (Gla-100) in a pooled population with T1DM from three
randomized, multicentre, 6-month similarly designed phase 3 trials: EDITION 4,
EDITION JP 1 and EDITION JUNIOR. Endpoints included incidence and time to first
occurrence of SH. Among 629 and 626 participants randomized to Gla-300 and
Gla-100, respectively, glycated haemoglobin reductions were similar. Fewer partici-
pants experienced ≥1 SH event with Gla-300 (6.2%) than with Gla-100 (9.3%). From
baseline to month 6, the risk of a first SH event was lower with Gla-300: hazard ratio
0.65 [95% confidence interval (CI) 0.44–0.98; stratified log-rank test P = 0.038].
SH event rates were numerically lower with Gla-300 versus Gla-100 from baseline to
month 6 [relative risk (RR) 0.80 (95% CI 0.49–1.29); P = 0.356] and baseline to week
8 [RR 0.73 (95% CI 0.37–1.44); P = 0.369]. Thus, Gla-300 demonstrated similar
glycaemic control with lower risk of SH versus Gla-100, particularly during the
titration period.
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1 | INTRODUCTION
Intensive insulin therapy to maintain glycaemic targets and reduce vascu-
lar complications exposes patients to increased risk of hypoglycaemia1
and its negative consequences.2,3 New-generation basal insulins may
reduce the risk of hypoglycaemia and improve glycaemic control.
Insulin glargine 300 U/mL (Gla-300) is a second-generation basal
insulin analogue that provides more evenly distributed pharmacoki-
netic and pharmacodynamic profiles beyond 24 hours, compared with
the first-generation insulin glargine 100 U/mL (Gla-100).4–6 In clinical
trials, Gla-300 and Gla-100 provided comparable glucose reductions,
but Gla-300 is associated with lower within-day variability, improved
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suppression of plasma glucagon and lipid metabolism, and reduced
rates of hypoglycaemia, despite greater insulin doses.5–7
The efficacy and safety of Gla-300 versus Gla-100 in participants
with type 1 diabetes (T1DM) were investigated in three phase 3, ran-
domized, open-label trials involving international (EDITION 4),8 Japa-
nese (EDITION JP 1)9 and paediatric (EDITION JUNIOR)10
populations. All studies had similar trial designs and demonstrated
non-inferiority in glycated haemoglobin (HbA1c) reduction with Gla-
300 versus Gla-100, while numerically fewer patients experienced
severe hypoglycaemia (SH) with Gla-300 than with Gla-100, during
the main 6-month treatment period.8–10
This post hoc meta-analysis aimed to further explore the risk of
SH with initiation of Gla-300 versus Gla-100 in adults, children and
adolescents with T1DM, who participated in the three pivotal EDI-
TION studies.
2 | METHODS
This meta-analysis evaluated pooled data from participants in EDI-
TION 4 (NCT01683266), EDITION JP 1 (NCT01689129) and EDI-
TION JUNIOR (NCT02735044), which were multicentre, randomized,
open-label, parallel-group phase 3 studies involving participants with
T1DM, as described previously and in the Supplementary Methods in
Appendix S1.8–11
All studies had the same primary endpoint: change in HbA1c from
baseline to week 26. In EDITION 4 and EDITION JP 1, participants
were aged ≥18 years with HbA1c ≥53 to ≥7.0%–≤10% (≤86 mmol/
mol) and had received basal plus prandial insulin for ≥1 year. In EDI-
TION JUNIOR, participants were aged 6 to 17 years with T1DM for
≥1 year and had received basal plus prandial insulin for ≥6 months,
with HbA1c ≥58 to ≥7.5%–≤11% (≤97 mmol/mol).
Participants followed a multiple daily injection regimen with basal
plus prandial insulin over 26 weeks (Figure S1 in Appendix S1),
titrated to a pre-breakfast self-monitored plasma glucose (SMPG) tar-
gets of 4.4 to 7.2 mmol/L (80–130 mg/dL) in EDITION 4 and EDI-
TION JP 1 and 5.0 to 7.2 mmol/L (90–130 mg/dL) in EDITION
JUNIOR (Table S1 in Appendix S1).8–10 Participants continued their
previous prandial insulin regimen, titrated at the investigator's
discretion.
Efficacy endpoints for this post hoc meta-analysis were change
from baseline to week 26 in mean HbA1c, mean laboratory-measured
fasting plasma glucose and mean pre-breakfast SMPG levels. Safety
endpoints included incidence and event rates of SH from baseline to
month 6 (main treatment period), baseline to week 8 (titration period),
and week 9 to month 6 (maintenance period). Changes in mean insulin
dose and mean body weight from baseline to week 26 were also
analysed, along with adverse events (AEs), including incidence of dia-
betic ketoacidosis and serious adverse events (SAEs).
In adults, SH was defined as a hypoglycaemic event that required
the assistance of another person to actively administer carbohydrate,
glucagon or other resuscitative actions. In children/adolescents, SH
was defined as an altered mental status and inability to assist in their
care, being semi-conscious or unconscious, or in a coma with or with-
out convulsions that may require parenteral therapy (glucagon and/or
glucose). SH events were assessed in all three clinical trials as part of
the safety endpoints, which were pre-specified and reported continu-
ously throughout the study, along with AEs.
In the meta-analysis, non-inferiority of Gla-300 versus Gla-100
for HbA1c reduction was defined as the upper bound of the 95% con-
fidence interval (CI) 0.3% (<3.3. mmol/mol) for the mean difference in
HbA1c. Efficacy and safety data observed during the main 6-month
treatment period were included in the analyses.
Efficacy analyses were performed on the efficacy population as
defined in each study (Supplementary Methods). Safety analyses were
performed on the safety population, which included all randomized
participants who received ≥1 dose of study insulin.
Continuous endpoints (eg, body weight, insulin dose, pre-break-
fast SMPG, fasting plasma glucose and HbA1c) were analysed using a
mixed-effect model for repeated measurements adjusted on treat-
ment, visit, treatment-by-visit interaction, baseline value and baseline-
by-visit interaction, and by adding fixed effects of study and study-
by-visit interaction for the T1DM study pool.
Incidences of participants with ≥1 SH event were compared
between treatment groups using an odds ratio based on a logistic
model with treatment as fixed effect, and by adding the study as fixed
effect for the T1DM study pool. The time to first event was assessed
via a hazard ratio estimated using a Cox proportional hazard model
with treatment group and study as fixed effects; log-rank test was
stratified by study, and cumulative incidence curves were calculated
using Kaplan–Meier estimates. Event rates were compared using rela-
tive risk (RR) based on a negative binomial model with treatment as a
fixed effect, logarithm of the treatment-emergent period as offset,
and by adding the study as a fixed effect for the T1DM study pool;
the cumulative curves of number of events were calculated using Nel-
son–Aalen estimates. AEs were analysed descriptively using number
and percentage of participants.
3 | RESULTS
Overall, 629 participants were randomized to Gla-300 treatment (EDI-
TION 4, n = 274; EDITION JP 1, n = 122; EDITION JUNIOR, n = 233),
and 626 participants to Gla-100 treatment [EDITION 4, n = 275; EDI-
TION JP 1, n = 121; EDITION JUNIOR, n = 230 (Figure S1)]. The effi-
cacy population included 628 and 624 participants in the Gla-300 and
Gla-100 group; the safety population included 629 and 624 partici-
pants in the Gla-300 and Gla-100 groups, respectively. The number of
participants who discontinued treatment during the 6-month treat-
ment period was similar between groups (Table S2).
Baseline characteristics in the pooled randomized population
were generally balanced between treatment groups (Table S3). The
majority were adults and white, 25% were Asian; approximately
one-third of participants were children/adolescents. Most used
Gla-100 as their basal insulin before study entry. The mean standard
deviation HbA1c level at baseline was 8.3 (0.8)% in both groups.
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Reductions in HbA1c from baseline to week 26 were similar in
both groups (Figure S2A). The least squares (LS) mean difference in
HbA1c between Gla-300 and Gla-100 was 0.05 (95% CI −0.044 to
0.150)%, demonstrating non-inferiority of Gla-300 versus Gla-100
(Figure S2B). While pre-breakfast SMPG initially increased in the Gla-
300 group, overall change was similar between the treatment groups
from baseline to week 26 (Figure S3). The LS mean (SE) change in
fasting plasma glucose was −0.84 (0.197) mmol/L in the Gla-300
group and − 1.09 (0.197) mmol/L in the Gla-100 group. Body weight
increased in both groups (Figure S4).
The incidence of SH with Gla-300 versus Gla-100 was not signifi-
cantly different across the individual EDITION studies, although SH
was numerically lower with Gla-300 (Figure 1). In the pooled analysis,
significantly fewer participants experienced ≥1 SH event from base-
line to month 6 with Gla-300 [39 (6.2%)] than Gla-100 [58 (9.3%);
hazard ratio 0.65 (95% CI 0.44 to 0.98); stratified log-rank test
P = 0.038 (Figure 1A)]. The odds ratio of ≥1 SH event with Gla-300
versus Gla-100 in the study pool was significant between baseline
and month 6 [0.65 (95% CI 0.42 to 0.98); P = 0.042], and between
baseline and week 8 [0.50 (95% CI 0.27 to 0.95); P = 0.033], but not
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F IGURE 1 A, Kaplan–Meier plot
showing cumulative incidence of the
time to first severe hypoglycaemia
(SH) event in participants with type 1
diabetes (T1DM) for the pooled
studies. B, Incidence of SH for the
individual studies and pooled studies
during the main 6-month treatment
period (safety populations). Odds
ratios (ORs) based on logistic models
with treatment as fixed effect and by
adding study as fixed effect for the
T1DM pooled studies. CI, confidence
interval; Gla-100, insulin glargine
100 U/mL; Gla-300, insulin glargine
300 U/mL
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significant between week 9 and month 6 [0.86 (95% CI 0.51 to 1.45);
P = 0.573 (Figure 1B)]. The incidence of SH was numerically lower
with Gla-300 versus Gla-100 between 6:00 and 11:59 AM (Figure S5).
The number of SH events reported with Gla-300 versus Gla-100
from baseline to month 6 was not significantly different across the
individual studies, or the pooled analysis; the number of SH events
from baseline to month 6 was 70 (0.23 events/participant-year) with
Gla-300 and 86 (0.29 events/participant-year) with Gla-100. The RR
of Gla-300 versus Gla-100 was 0.80 (95% CI 0.49 to 1.29; P = 0.356)
from baseline to month 6, 0.73 (95% CI 0.37 to 1.44; P = 0.369) from
baseline to week 8, and 0.84 (95% CI 0.45 to 1.57; P = 0.590) from
week 9 to month 6 (Figure 2).
The basal insulin dose increased in both treatment groups from
baseline [LS mean (SE) 0.36 (0.007) U/kg for Gla-300 and 0.37 (0.007)
U/kg for Gla-100] to week 26 [LS mean (SE) 0.50 (0.006) U/kg for
Gla-300 and 0.43 (0.006) U/kg for Gla-100 (Figure S3)]. The daily
prandial insulin dose remained almost stable across the two groups,
from baseline [LS mean (SE) 0.40 (0.009) U/kg for Gla-300 and 0.39
(0.008) U/kg for Gla-100] to week 26 [LS mean (SE) 0.41 (0.007) U/kg
for Gla-300 and 0.41 (0.007) U/kg for Gla-100].
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F IGURE 2 A, Cumulative mean
number of events of severe
hypoglycaemia (SH) per participant
for the pooled studies. B, Event rates
and relative risk (RR) of SH events for
the individual studies and the pooled
studies, during the main 6-month
treatment period (safety populations).
aModel calculated with low number of
events (3 vs. 6). RR based on negative
binomial models with treatment as
fixed effect, and logarithm of the
treatment-emergent period as offset,
and by adding study as fixed effect
for the type 1 diabetes (T1DM)
pooled studies; cumulative mean
number calculated using Nelson–
Aalen estimates. CI, confidence
interval; Gla-100, insulin glargine
100 U/mL; Gla-300, insulin glargine
300 U/mL
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Overall, 395 (62.8%) and 388 participants (62.2%) experienced
AEs in the Gla-300 and Gla-100 groups. Diabetic ketoacidosis
occurred in two (0.3%) and five participants (0.8%), and SAEs were
experienced by 37 (5.9%) and 46 participants (7.4%) in the Gla-300
and Gla-100 groups, respectively. Two deaths occurred in the Gla-
300 group: one from suicide, the other from a cardiac event; neither
was considered related to study drug. The number of participants
who discontinued treatment owing to AEs was 6 (1.0%) with Gla-300
and 5 (0.8%) with Gla-100.
4 | DISCUSSION
In this patient-level meta-analysis of three EDITION studies, a signifi-
cantly lower risk of SH with Gla-300 versus Gla-100 was observed
from baseline to month 6, when data from the three clinical trials were
pooled. This result was primarily driven by a lower SH risk during the
first 8 weeks (Figure 1B), suggesting that Gla-300 may be useful in
limiting the risk of SH, especially during the phase of most active insu-
lin titration. Indeed, the number of participants needed to be treated
with Gla-300 rather than Gla-100 in order to prevent one participant
experiencing SH was 45 in the first 8 weeks of treatment (titration
period), and 33 in the overall 6-month period, which is clinically mean-
ingful compared with a number needed to treat of 148 from week 9
to month 6.
While the results of this analysis may be attributable to the
increased power gained from analysing the pooled population with
T1DM, it nonetheless underpins a clinically meaningful advantage
with Gla-300 versus Gla-100 that was identifiable as a trend in the
individual studies. Notably, the decreased risk of SH with Gla-300
was achieved alongside similar HbA1c reductions of 0.4%, and simi-
lar overall safety profiles, in both treatment groups.
The reduced SH risk with Gla-300 versus Gla-100 may be attrib-
utable to the more favourable pharmacokinetic/pharmacodynamic
profile of Gla-300 versus Gla-100.5 The smoother average 24-hour
glucose profile of Gla-300 may also reduce glycaemic variability,
irrespective of morning or evening injection, rendering it a more flexi-
ble basal insulin analogue than Gla-100.6 These more physiological
characteristics of Gla-300 may explain the reduction of SH in the early
and late morning hours (6:00 to 11:59 AM; Figure S5), in line with simi-
lar observations in studies of people with type 2 diabetes.12,13 Nota-
bly, pre-breakfast SMPG was slightly higher with Gla-300 versus
Gla-100 initially following the switch to Gla-300, despite greater
doses of Gla-300 (Figure S3). This suggests that a transient, slight
increase of fasting glycaemic levels during titration with Gla-300 may
reduce the SH risk more effectively than Gla-100, supported by the
separation of the risk curves for Gla-300 and Gla-100 shortly after
Gla-300 treatment initiation (Figure 1A).
The findings of this meta-analysis are consistent with those of
real-world analyses. In one retrospective study, the number of noctur-
nal hypoglycaemic events was significantly reduced within 2 weeks
after patients with T1DM were switched from Gla-100 to Gla-300.14
In the SPARTA study, the incidence of SH remained similar before and
6 months after initiation of Gla-300, despite a significant HbA1c
reduction of 0.4%.15
This post hoc, exploratory analysis has some limitations. For exam-
ple, it includes a heterogeneous population from the three EDITION
studies; however, this population is also representative of a large mul-
tinational cohort of patients with T1DM. Other factors that may
impact the occurrence of SH, such as changes in carbohydrate intake,
physical activity and stress, were not accounted for in this meta-analy-
sis. Additionally, data collection pertaining to SH events was depen-
dent on participant reporting; however, the prospective clinical trial
setting with pre-specified hypoglycaemia endpoints, an above-aver-
age visit schedule and robust monitoring efforts may provide confi-
dence in the reported results. Strengths of the analysis are the
similarity between study designs and use of patient-level data.
In summary, this meta-analysis suggests Gla-300 may hold a clini-
cally important advantage over Gla-100 with respect to fewer SH
events, particularly during the titration period, while providing simi-
larly improved glycaemic control in people with T1DM.
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